# Dulaglutide (Trulicity)

> Once-weekly GLP-1 agonist with cardiovascular benefit.

Source: https://peptides.cafe/peptide/dulaglutide
Category: GLP-1 Agonist · Metabolic
Tag: FDA-Approved · Metabolic

## Mechanism
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.

## Research areas
- Type 2 diabetes
- Cardiovascular risk reduction in T2D

## Common research protocols
- Weekly: 0.75–4.5 mg SC once weekly.

## Study summaries
- "REWIND trial" — Lancet (2019): Reduced major adverse cardiovascular events in T2D patients with or without prior CV disease.

## Considerations
- FDA-approved.
- Boxed warning: thyroid C-cell tumors in rodents.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.